In an effort to find more therapies for both common and rare diseases, AstraZeneca (AZ) has released 22 of its failed drugs to academic researchers, with the hope that the drugs will have a second chance. The program is a collaboration between the United Kingdom’s Medical Research Council (MRC) and AZ. The MRC is providing $11 million in funding to 15 labs that will investigate alternative uses of the failed drugs. The 15 research groups that will be participating in the program were selected from a field of 100 applicants. We are pleased to report that one of the research groups will be testing some of the failed compounds as potential therapies for ALS!
Click here to read more.Share this: